检索结果-南通市图书馆

World Journal of Gastroenterology 2005年第42期11卷 6701-6706页

作者： Terence CW Poon Clarissa HS Chiu Paul BS Lai tony SK mok Benny Zee Anthony TC Chan Joseph JY Sung Philip J Johnson Department of Medicine and Therapeutics Sir YK Pao Cancer Centre the Chinese University of Hong Kong Prince of Wales Hospital NT Hong Kong China Department of Clinical Oncology Sir YK Pao Cancer Centre the Chinese University of Hong Kong Prince of Wales Hospital NT Hong Kong China Department of Surgery Sir YK Pao Cancer Centre the Chinese University of Hong Kong Prince of Wales Hospital NT Hong Kong China Cancer Research UK Institute for Cancer Studies University of Birmingham Vincent Drive Edgbaston Birmingham B15 2TT United Kingdom

AIM： To investigate the correlation between tissue ST6Gal I and serum msAFP in HCC patients, and to investigate their prognostic significance. METHODS： Preoperative sera, paired tumorous and non-tumorous tissues were collected from 19 consecutive patients who had undergone surgical resection of HCC. ST6Gal I activities in the tissues were measured by an in vitro microsomal enzyme activity assay. The percentages of tumor-specific msAFP in the sera were also estimated by an isoelectric focusing-immunoblotting assay. RESULTS： The tumor ST6Gal I activity was negatively correlated with serum msAFP percentage （r = -0.53, P = 0.019）. Both decreased tumor ST6Gal I activity and increased serum msAFP percentage were associated with poor tumor cell differentiation. Univariate analyses showed that both decreased tumor ST6Gal I activity （P = 0.028）, increased serum msAFP percentage （P = 0.034） and poor tumor cell differentiation （P = 0.031）were associated with shorter overall survival. Multivariate analysis using the Cox regression model showed that the preoperative serum msAFP percentage （P = 0.022） and tumor cell differentiation status （P = 0.048） were independent prognostic indicators for patient overall survival. CONCLUSION： Our results indicate that the presence of msAFP in blood circulation is associated with a decreased activity of ST6Gal I activity in HCC. Both tissue ST6Gal I and serum msAFP are potential prognostic markers for patients with operable HCC.

关键词： Alpha-fetoprotein Beta-galactoside alpha-2,6-sialyltransferase Hepatocellular carcinoma Patientsurvival Cell differentiation

APPLYING GCP GUIDELINE ON CLINICAL TRAILS OF TRADITIONAL CHINESE MEDICINE

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

APPLYING GCP GUIDELINE ON CLINICAL TRAILS OF TRADITIONAL CHI...

A new horizon of targeted therapy in management of lung cancer

中国抗癌协会第六届临床肿瘤协作中心（CSCO）学术年会

作者： tony SK mok Benny Zee Department of Clinical Oncology The Chinese University of Hong Kong Hong Kong China Department of Clinical Oncology The Chinese University of Hong Kong Hong Kong China

＜正＞Introduction Traditional Chinese medicine （TCM） is currently, de facto, an integral part of the health care system in China. The majority of the population uses TCM and western medicines inter changeably for h...

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

中国肺癌杂志 2004年第4期7卷 276-283页

作者： tony mok Department of Clinical Oncology the Chinese University of Hong Kong Hong Kong P.R.China BMSc MD FRCPC FHKAM FHKCP

1 IntroductionCisplatin-based combination chemotherapy using one of the novel cytotoxic agents, such as gemcitabine or taxane, prolongs survival of patients with advanced non-small cell lung cancer (NSCLC). The recent published phase Ⅲ study that compared paclitaxel/cisplatin to gemcitabine/cisplatin, docetaxel/cisplatin or paclitaxel/carboplatin has shown equal efficacy with the exception of longer progression-free survival from the gemcitabine/cisplatin combination[1]. Overall tumor response rates of 1 155 eligible patients was 19% with median survival of 7. 9months only. Findings from other major randomized comparative studies were similar. Table 1 summarized the tumor response rate and survival of these studies[1-4]. Hundreds of patients received platinumbased new drug doublets and the overall response rate was persistently reported at only about 20% to 30%. Survivals were better than the first generation of combination chemotherapy but the best median survival was less than 10 months and 1-year survival rate was persistently less than 45 %.

关键词：靶向治疗肺癌肿瘤 NSCLC 化学疗法

Immediate Versus Delayed Treatment with EGFR Tyrosine Kinase Inhibitors after First-line Therapy in Advanced Non-small-cell Lung Cancer

在线全文

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2011年第2期23卷 112-117页

作者： Zhi-jie Wang Tong-tong An tony mok Lu Yang Hua Bai Jun Zhao Jian-chun Duan Mei-na Wu Yu-yan Wang Ping-ping Li Hong Sun Ping Yang Jie Wang Key Laboratory of Carcinogenesis and Translational Research （Ministry of Education） Department of Thoracic Medical Oncology Department of Integrative Medicine Peking University School of Oncology Beijing Cancer Hospital ＆ Institute Beijing China Department of Clinical Oncology Chinese University of Hong Kong Hong Kong China Department of Oncology General Hospital of Navy Beijing China

Objective： To analyze the outcomes of patients who received TKI immediately after the first-line without progression as maintenance treatment （immediate group） vs. those received delayed treatment upon disease progression as second-line therapy （delayed group）. Methods： The study included 159 no-small-cell lung cancer （NSCLC） patients who received gefitinib or erlotinib as maintenance treatment in the immediate group （85 patients） or as second-line therapy in the delayed group （74 patients）. The primary end point was progression-free survival （PFS）. EGFR mutation status was detected using denaturing high-performance liquid chromatography （DHPLC）. Results： PFS was 17.3 and 16.4 months in the immediate and delayed groups, respectively （hazard ratio [HR], 0.99; 95% Confidence Interval [CI]： 0.69-1.42; P=0.947）. In a subgroup analysis that included only patients with EGFR mutation, however, PFS was significantly longer in the immediate group than in the delayed group （HR, 0.48; 95% CI： 0.27-0.85; P=0.012）. In patients with wild type EGFR, the risk for disease progression was comparable between the two groups （HR, 1.23; 95% CI： 0.61-2.51; P=0.564）. No significant difference was demonstrated between the immediate and delayed group in terms of the overall survival （OS）（26.1 months vs. 21.6 months, respectively; HR=0.53; 95% CI： 0.27 to 1.06; P=0.072）. There was also no difference in the incidence of adverse events between the two groups. Conclusions： EGFR TKI maintenance improves PFS in patients with EGFR mutation. Prospectively designed clinical studies that compare TKI immediate vs. delayed treatment after first-line chemotherapy upon disease progression are needed.

关键词： EGFR tyrosine kinase inhibitor Maintenance therapy Non-small-cell lung cancer

在线全文

学校读者我要写书评

暂无评论

关于“肺癌的预防和治疗”的调查

中国处方药 2003年第5期2卷 70-72页

作者： tony mok BMSc MD 香港中文大学皇家威尔斯亲王医院肿瘤科

肺癌是世界上最为常见的癌症,是男性最常见、女性第二常见的癌症。

关键词：肺癌治疗药物肿瘤

在线全文

学校读者我要写书评

暂无评论

GCP指引在中医临床试验中的应用

循证医学 2004年第2期4卷 69-71,77页

作者： tony SK mok Benny Zee 马冬香港中文大学临床肿瘤系广东省人民医院肿瘤中心广州510080

1引言事实上,中医(traditional Chinese medicine,TCM)是现时中国医疗保健体制不可缺少的一部分.从伤风感冒到恶性肿瘤,无论大病小病大部分居民都会使用TCM或西医来进行治疗.中国政府早已承认中西医两种医疗体系,而且TCM在费用上占医... 详细信息

1引言事实上,中医(traditional Chinese medicine,TCM)是现时中国医疗保健体制不可缺少的一部分.从伤风感冒到恶性肿瘤,无论大病小病大部分居民都会使用TCM或西医来进行治疗.中国政府早已承认中西医两种医疗体系,而且TCM在费用上占医疗总额的40%左右[1].…… 作者简介：tony SK mok(1960-),男,福建漳洲人,副教授,医学博士,主要研究方向为肺癌、肝癌的临床研究及中西药联合应用.

关键词： GCP 中医临床试验 TCM 方剂

中国间变性淋巴瘤激酶阳性、ROS1阳性非小细胞肺癌诊疗指南

在线全文

学校读者我要写书评

暂无评论

中华病理学杂志 2018年第4期47卷 241-247页

作者：张绪超陆舜黄诚刘晓晴杨衿记宋勇张力廖美琳王长利程颖李甘地 tony mok 莫树锦王洁王孟昭张沂平周建英周晓军周晓燕林冬梅胡成平王凯何勇李慧钟文昭吴一龙广东省肺癌研究所广东省人民医院广东省医学科学院上海交通大学附属胸科医院中山大学肿瘤医院天津肿瘤医院吉林省肿瘤医院四川大学华西医院病理科香港中文大学医学院福建省肿瘤医院解放军第三0七医院北京大学肿瘤医院北京协和医院浙江省肿瘤医院浙江大学医学院附属第一医院解放军南京总医院复旦大学附属肿瘤医院病理科中南大学湘雅医院浙江大学医学院附属第二医院陆军军医大学大坪医院

原发性肺癌（简称肺癌）是我国最常见的恶性肿瘤之一。根据国家癌症中心公布的2015年癌症统计数据显示，2015年，我国新发肺癌患者例数达73．3万，死亡例数60．0万。居所有恶性肿瘤之首，其中80％以上的患者为非小细胞肺癌（non—small ... 详细信息

原发性肺癌（简称肺癌）是我国最常见的恶性肿瘤之一。根据国家癌症中心公布的2015年癌症统计数据显示，2015年，我国新发肺癌患者例数达73．3万，死亡例数60．0万。居所有恶性肿瘤之首，其中80％以上的患者为非小细胞肺癌（non—small cell lung cancer）。

关键词：非小细胞肺癌间变性淋巴瘤激酶诊疗指南阳性中国数据显示恶性肿瘤肺癌患者

中国间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌诊断专家共识(2013版)

在线全文

学校读者我要写书评

暂无评论

中华病理学杂志 2013年第6期42卷 402-406页

作者：张绪超陆舜张力王长利程颖李甘地 tony mok 黄诚刘晓晴王洁王孟昭张沂平周建英周晓燕林冬梅杨衿记李慧陈海泉钟文昭吴一龙广东省肺癌研究所广东省人民医院广东省医学科学院上海交通大学附属胸科医院中山大学附属肿瘤医院天津医科大学附属肿瘤医院吉林省肿瘤医院四川大学华西医院香港中文大学医学院福建省肿瘤医院解放军307医院北京大学肿瘤医院中国医学科学院北京协和医学院北京协和医院浙江省肿瘤医院浙江大学医学院附属第一医院复旦大学附属肿瘤医院中国医学科学院北京协和医学院肿瘤医院广东省肺癌研究所广东省人民医院广东省医学科学院

随着分子医学进展和靶向药物的不断涌现,晚期非小细胞肺癌(NSCLC)的治疗已进入到个体化治疗的时代。目前临床应用的个体化靶向治疗主要针对表皮生长因子受体(EGFR)基因突变性和间变性淋巴瘤激酶(ALK)融合基因阳性肺癌,这两种基因变异型... 详细信息

随着分子医学进展和靶向药物的不断涌现,晚期非小细胞肺癌(NSCLC)的治疗已进入到个体化治疗的时代。目前临床应用的个体化靶向治疗主要针对表皮生长因子受体(EGFR)基因突变性和间变性淋巴瘤激酶(ALK)融合基因阳性肺癌,这两种基因变异型肺癌均具有明确的分子靶点、靶点检测技术及上市的靶向药物,临床疗效得到明显提高。其他基因变异型肺癌的靶向药物和伴随分子诊断

关键词：淋巴瘤非小细胞肺癌突变性和间变性淋巴瘤

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

吉非替尼或卡铂-紫杉醇治疗肺腺癌观察

中国处方药 2009年第10期8卷 47-47页

作者： tony S．mok Yi-Long Wu Sumitra Thongprasert

背景及目的：之前的非对照研究表明，吉非替尼一线治疗对某些非小细胞肺癌患者有效，本研究比较了吉非替尼与卡铂-紫杉醇治疗肺腺癌的临床疗效。

关键词：吉非替尼一线治疗肺腺癌紫杉醇卡铂肺癌患者非小细胞临床疗效